Ampac Fine Chemicals (AFC) has completed a contract manufacturing agreement with Chimerix for the manufacturing process of Chimerix's smallpox drug, CMX001 active pharmaceutical ingredient (API).
Subscribe to our email newsletter
The API will be manufactured at AFC’s recently completed second semi-works unit, which is located within a secured perimeter segment of AFC on the DoD-regulated campus of Aerojet/GenCorp in Rancho Cordova.
AFC Product Management executive director Larry Zeagler said this facility offers a remotely operated process plant which can safely run hydrogenations and hazardous chemical processes, while containing reactants and products with Occupational Exposure Limits (OELs) down to 0.5µg/m3, combining two of the core strengths of AFC.
"Equipment consists of 4 reactors (from 300-750 gal) and one 2.0m2 Hastelloy filter-dryer and the unit is ideally suited for the production of APIs required by companies like Chimerix," Zeagler said.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.